Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) Director Evan Lockwood Rachlin purchased 718,750 shares of the business’s stock in a transaction that occurred on Friday, October 16th. The stock was bought at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director owned 2,588,248 shares in the company, valued at $41,411,968. This represents a 38.45% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Iambic Therapeutics Stock Down 1.3%
NASDAQ:IAM opened at $15.80 on Thursday. Iambic Therapeutics, Inc. has a fifty-two week low of $14.10 and a fifty-two week high of $25.00.
Iambic Therapeutics Company Profile
Iambic Therapeutics, Inc (NASDAQ: IAM) is a clinical-stage biotechnology company focused on discovering and developing novel medicines, with an emphasis on small-molecule therapies. The company combines artificial intelligence, computational modeling and experimental drug discovery methods to identify potential drug candidates and accelerate the development process.
Iambic’s technology platform is designed to support multiple stages of pharmaceutical research, including target evaluation, molecule design, compound testing and optimization.
See Also
- Five stocks we like better than Iambic Therapeutics
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
